Editorial Policy

Content Creation Process

Content on DecodeMyBio is written against peer-reviewed literature, published clinical guidelines, and regulatory sources such as FDA drug labeling. Articles, gene pages, and medication pages are written in plain language for educational purposes. We aim to make pharmacogenomic concepts accessible without oversimplifying the underlying science or making claims that extend beyond the supporting evidence.

Who Writes This Content

Content on DecodeMyBio is written and maintained by one person: its founder, Vytautas Jazbutis. He is not a geneticist, a pharmacist, or a physician. There is no editorial team and no clinical reviewer, and we do not claim one. What happens instead:

• Sourcing — claims are written against published primary sources: CPIC and DPWG drug-gene guidelines, PharmVar allele definitions, ClinVar variant classifications, and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. Articles carry a References list naming the guidelines, labels and PubMed-indexed papers they rest on.
• Hedging — where the evidence is weak, contested, or absent, the text is meant to say so rather than round up to a confident answer.
• Re-review — published content is revisited when CPIC or DPWG release updated guidelines, or when new evidence materially changes a recommendation. The visible "last reviewed" date on a page changes only after an actual re-read, not for freshness.
• Corrections — factual errors are fixed and recorded publicly in the corrections log, with what was wrong and what changed.

To understand how we apply these standards in our analysis pipeline, see our methodology and data sources.

Evidence Standards

DecodeMyBio relies primarily on the following sources:

• CPIC — Clinical Pharmacogenetics Implementation Consortium guidelines for drug-gene interactions.
• PharmGKB — Pharmacogenomics knowledge base for guideline annotations and clinical evidence summaries.
• FDA — Table of Pharmacogenomic Biomarkers in Drug Labeling, used for contextual regulatory information.
• PharmVar — Pharmacogene Variation Consortium for allele definitions and nomenclature.

We do not use non-evidence-based supplement protocols, proprietary algorithms without published methodology, or unpublished data sources. To see how this compares with other testing services, read our pharmacogenomic testing comparison. For details on how we apply these sources in our analysis, see our Methodology page.

Conflict of Interest Disclosure

DecodeMyBio offers Decode, a one-time pharmacogenomic analysis generated from consumer DNA data, plus an optional Decode+ Monitoring subscription. All educational content — including articles, gene pages, and medication pages — is written to inform, not to promote a purchase. Content is designed to be useful regardless of whether a reader uses DecodeMyBio's services.

DecodeMyBio does not accept advertising, sponsored content, or affiliate payments from pharmaceutical companies, testing laboratories, or supplement manufacturers.

Medical Disclaimer Policy

DecodeMyBio is not a medical device, diagnostic tool, or healthcare provider. All content — including educational articles, gene and medication pages, and results — is informational only. No content on this site constitutes medical advice or a recommendation to start, stop, or change any medication.

Users should always consult a qualified healthcare provider before making medication decisions. For a detailed discussion of the analytical boundaries of consumer pharmacogenomic analysis, see our limitations page.

Corrections Policy

If you identify an error in any content on DecodeMyBio — whether factual, typographic, or interpretive — please contact us at support@decodemybio.com. We are committed to reviewing all reported inaccuracies and issuing corrections promptly. Substantive factual corrections are recorded in our public corrections log.